0.83
price up icon0.30%   0.0025
after-market Handel nachbörslich: .84 0.01 +1.20%
loading
Schlusskurs vom Vortag:
$0.8275
Offen:
$0.8178
24-Stunden-Volumen:
444.30K
Relative Volume:
0.35
Marktkapitalisierung:
$212.27M
Einnahmen:
$60.28M
Nettoeinkommen (Verlust:
$-113.87M
KGV:
-1.5549
EPS:
-0.5338
Netto-Cashflow:
$-145.76M
1W Leistung:
+17.81%
1M Leistung:
-12.72%
6M Leistung:
-30.25%
1J Leistung:
+48.21%
1-Tages-Spanne:
Value
$0.792
$0.83
1-Wochen-Bereich:
Value
$0.6702
$0.8552
52-Wochen-Spanne:
Value
$0.42
$2.05

Adaptimmune Therapeutics Plc Adr Stock (ADAP) Company Profile

Name
Firmenname
Adaptimmune Therapeutics Plc Adr
Name
Telefon
44 1235 430000
Name
Adresse
60 JUBILEE AVENUE, ABINGDON, OXFORDSHIRE
Name
Mitarbeiter
449
Name
Twitter
@Adaptimmune
Name
Nächster Verdiensttermin
2024-11-13
Name
Neueste SEC-Einreichungen
Name
ADAP's Discussions on Twitter

Adaptimmune Therapeutics Plc Adr Stock (ADAP) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2023-03-24 Eingeleitet Bryan Garnier Buy
2023-01-03 Hochstufung Guggenheim Neutral → Buy
2022-11-09 Hochstufung Mizuho Neutral → Buy
2021-05-28 Eingeleitet Barclays Underweight
2020-04-22 Eingeleitet Mizuho Neutral
2019-08-02 Herabstufung Guggenheim Buy → Neutral
2019-05-31 Eingeleitet ROTH Capital Buy
2019-05-30 Fortgesetzt Citigroup Buy
2019-05-07 Herabstufung SVB Leerink Outperform → Mkt Perform
2017-03-17 Eingeleitet Wells Fargo Market Perform
2016-10-24 Herabstufung BofA/Merrill Neutral → Underperform
2016-09-30 Eingeleitet Raymond James Outperform
2016-02-25 Eingeleitet Citigroup Buy
2015-06-01 Eingeleitet BofA/Merrill Neutral
2015-06-01 Eingeleitet Guggenheim Buy
2015-06-01 Eingeleitet Leerink Partners Outperform
Alle ansehen

Adaptimmune Therapeutics Plc Adr Aktie (ADAP) Neueste Nachrichten

pulisher
Nov 01, 2024

Adaptimmune faces Nasdaq delisting over share price - Investing.com India

Nov 01, 2024
pulisher
Oct 17, 2024

NVIDIA Corp (NVDA): Be Patient, You Will Learn - Stocks Register

Oct 17, 2024
pulisher
Oct 16, 2024

Investing in HUYA Inc ADR (HUYA): What You Must Know - Knox Daily

Oct 16, 2024
pulisher
Oct 16, 2024

Checking in on Blackstone Inc (BX) after recent insiders movement - Knox Daily

Oct 16, 2024
pulisher
Oct 16, 2024

Ready to Jump After Recent Trade: Adaptimmune Therapeutics Plc ADR (ADAP) - SETE News

Oct 16, 2024
pulisher
Oct 14, 2024

Ratio Examination: Adaptimmune Therapeutics Plc ADR (ADAP)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex

Oct 14, 2024
pulisher
Oct 14, 2024

Was anything negative for Adaptimmune Therapeutics Plc ADR (ADAP) stock last session? - US Post News

Oct 14, 2024
pulisher
Oct 10, 2024

Chief Commercial Officer Piccina Cintia sale 24,531 shares of Adaptimmune Therapeutics Plc ADR [ADAP] - Knox Daily

Oct 10, 2024
pulisher
Oct 09, 2024

The Significance of Moving Averages in Adaptimmune Therapeutics Plc ADR Inc. (ADAP) Price Performance - The InvestChronicle

Oct 09, 2024
pulisher
Oct 08, 2024

Technical analysis of Adaptimmune Therapeutics Plc ADR (ADAP) stock chart patterns - US Post News

Oct 08, 2024
pulisher
Oct 07, 2024

Adaptimmune Therapeutics Plc ADR (ADAP)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex

Oct 07, 2024
pulisher
Oct 04, 2024

A significant driver of top-line growth: Adaptimmune Therapeutics Plc ADR (ADAP) - SETE News

Oct 04, 2024
pulisher
Oct 02, 2024

Analysts review Adaptimmune Therapeutics Plc ADR’s rating - Knox Daily

Oct 02, 2024
pulisher
Oct 02, 2024

How should investors view Adaptimmune Therapeutics Plc ADR (ADAP)? - US Post News

Oct 02, 2024
pulisher
Oct 02, 2024

Recent Insider Activity Could Benefit Zentalis Pharmaceuticals Inc (ZNTL) - Knox Daily

Oct 02, 2024
pulisher
Sep 27, 2024

Wall Street SWOT: Adaptimmune stock faces challenges despite FDA win - Investing.com

Sep 27, 2024
pulisher
Sep 25, 2024

Stocks of Adaptimmune Therapeutics Plc ADR (ADAP) are poised to climb above their peers - SETE News

Sep 25, 2024
pulisher
Sep 25, 2024

Insider Sale Alert: Gap, Inc. [GAP] – Is it Time to sell? - Knox Daily

Sep 25, 2024
pulisher
Sep 25, 2024

Adaptimmune Therapeutics Plc ADR [ADAP] Piccina Cintia sells 24,531 Shares for $22814.0 - Knox Daily

Sep 25, 2024
pulisher
Sep 24, 2024

Adaptimmune finalizes settlement with Genentech - Investing.com India

Sep 24, 2024
pulisher
Sep 23, 2024

ADAP’s price-to-sales ratio: Is it a good investment opportunity? - US Post News

Sep 23, 2024
pulisher
Sep 23, 2024

Ratios Uncovered: Breaking Down Adaptimmune Therapeutics Plc ADR (ADAP)’s Trailing Twelve Months Metrics - The Dwinnex

Sep 23, 2024
pulisher
Sep 20, 2024

Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing - Yahoo Finance UK

Sep 20, 2024
pulisher
Sep 20, 2024

Adaptimmune Therapeutics Plc ADR Inc. (ADAP) Price Performance: Is It Undervalued or Overvalued? - The InvestChronicle

Sep 20, 2024
pulisher
Sep 18, 2024

Recent Insider Activity Could Benefit Adaptimmune Therapeutics Plc ADR (ADAP) - Knox Daily

Sep 18, 2024
pulisher
Sep 18, 2024

Zumiez Inc’s latest rating changes from various analysts - Knox Daily

Sep 18, 2024
pulisher
Sep 17, 2024

AdaptHealth Stock Earns RS Rating Upgrade - MSN

Sep 17, 2024
pulisher
Sep 17, 2024

A new trading data show Adaptimmune Therapeutics Plc ADR (ADAP) is showing positive returns. - SETE News

Sep 17, 2024
pulisher
Sep 16, 2024

Predicting Adaptimmune Therapeutics Plc ADR’s (ADAP) earnings for the current quarter - US Post News

Sep 16, 2024
pulisher
Sep 13, 2024

Director SIMON WILLIAM E JR acquire 45,000 shares of Douglas Emmett Inc [DEI] - Knox Daily

Sep 13, 2024
pulisher
Sep 13, 2024

Buying Buzz: Noble Corp Plc [NE] 10% Owner APMH Invest A/S purchases 324,984 shares of the company - Knox Daily

Sep 13, 2024
pulisher
Sep 10, 2024

There is no doubt that Adaptimmune Therapeutics Plc ADR (ADAP) ticks all the boxes. - SETE News

Sep 10, 2024
pulisher
Sep 09, 2024

Analyzing Ratios: Adaptimmune Therapeutics Plc ADR (ADAP)’s Financial Story Unveiled - The Dwinnex

Sep 09, 2024
pulisher
Sep 09, 2024

Adaptimmune Therapeutics Plc ADR (ADAP) stock analysis: A simple moving average approach - US Post News

Sep 09, 2024
pulisher
Sep 06, 2024

A company insider recently sold 24,531 shares of Adaptimmune Therapeutics Plc ADR [ADAP]. Should You Sale? - Knox Daily

Sep 06, 2024
pulisher
Sep 06, 2024

EWCZ Shares Experience Decline in Value - Knox Daily

Sep 06, 2024
pulisher
Sep 06, 2024

Natera Inc [NTRA] Shares Jump Approximately 97.71% Over the Year - Knox Daily

Sep 06, 2024
pulisher
Sep 06, 2024

Adaptimmune Therapeutics Plc ADR’s: Contrasting Stock Performances in a Volatile Market - The InvestChronicle

Sep 06, 2024
pulisher
Sep 06, 2024

Premier Inc [PINC] Shares Fall -1.35 % on Thursday - Knox Daily

Sep 06, 2024
pulisher
Sep 05, 2024

An analyst sees good growth prospects for Adaptimmune Therapeutics Plc ADR (ADAP) - SETE News

Sep 05, 2024
pulisher
Sep 05, 2024

Closing Figures: Adaptimmune Therapeutics Plc ADR (ADAP)’s Negative Finish at 1.16, Down -4.13 - The Dwinnex

Sep 05, 2024
pulisher
Aug 28, 2024

Analyzing Adaptimmune Therapeutics Plc ADR (ADAP) After Recent Trading Activity - Knox Daily

Aug 28, 2024
pulisher
Aug 28, 2024

Adaptimmune Therapeutics Plc ADR (ADAP) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News

Aug 28, 2024
pulisher
Aug 28, 2024

Market Recap Check: Adaptimmune Therapeutics Plc ADR (ADAP)’s Negative Finish at 1.24, Up/Down -6.77 - The Dwinnex

Aug 28, 2024
pulisher
Aug 27, 2024

Adaptimmune Therapeutics Plc ADR: Rising -35.12% from 52-Week Low, Can the Stock Stay Afloat? - The InvestChronicle

Aug 27, 2024
pulisher
Aug 26, 2024

A closer look at Adaptimmune Therapeutics Plc ADR (ADAP)’s stock price trends - US Post News

Aug 26, 2024
pulisher
Aug 22, 2024

Adaptimmune Therapeutics Plc ADR (ADAP) Stock: 52-Week Performance Insights and Trading Volume - The InvestChronicle

Aug 22, 2024
pulisher
Aug 21, 2024

A better buy-in window may exist right now for Adaptimmune Therapeutics Plc ADR (ADAP) - SETE News

Aug 21, 2024
pulisher
Aug 20, 2024

Financial Analysis: Adaptimmune Therapeutics Plc ADR (ADAP)’s Ratios Unveil Key Insights - The Dwinnex

Aug 20, 2024
pulisher
Aug 19, 2024

The Adaptimmune Therapeutics Plc ADR (ADAP) had a good session last reading, didn’t it? - US Post News

Aug 19, 2024
pulisher
Aug 14, 2024

It is Poised to be a Bull Market for Adaptimmune Therapeutics Plc ADR (ADAP) - SETE News

Aug 14, 2024

Finanzdaten der Adaptimmune Therapeutics Plc Adr-Aktie (ADAP)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Adaptimmune Therapeutics Plc Adr-Aktie (ADAP) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Rawcliffe Adrian
Chief Executive Officer
Jan 17 '24
Sale
0.67
30,080
20,244
44,848
Rawcliffe Adrian
Chief Executive Officer
Jan 16 '24
Sale
0.79
9,304
7,350
14,104
Norry Elliot
Chief Medical Officer
Jan 17 '24
Sale
0.67
18,276
12,300
7,785
Norry Elliot
Chief Medical Officer
Jan 16 '24
Sale
0.79
2,287
1,807
3,363
Lunger John
Chief Patient Supply Officer
Jan 17 '24
Sale
0.67
18,114
12,191
7,785
Lunger John
Chief Patient Supply Officer
Jan 16 '24
Sale
0.79
4,681
3,698
7,023
Bertrand William C JR
Chief Operating Officer
Jan 17 '24
Sale
0.67
18,908
12,725
7,785
Bertrand William C JR
Chief Operating Officer
Jan 16 '24
Sale
0.79
4,681
3,698
7,023
Norry Elliot
Chief Medical Officer
Jan 12 '24
Sale
0.85
7,799
6,661
11,841
Norry Elliot
Chief Medical Officer
Jan 11 '24
Sale
0.84
4,009
3,354
6,104
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
Kapitalisierung:     |  Volumen (24h):